Tenpoint to treat vision loss


United Kingdom

A new company has launched in the UK with the goal of using both ex vivo and in vivo cell therapy approaches for the treatment of ocular diseases. Tenpoint Therapeutics Ltd disclosed its plans on 12 July and concurrently announced a $70 million Series A financing led by F-Prime Capital, Sofinnova Partners, and British Patient Capital. The UCL Technology Fund was also part of the financing syndicate.